Worst Subject of of First-in-man study · YYNN

First-in-man study

Subject of

Popular
Trending
Worst
Worst
- Popular
- Trending
- New
- Best
- Worst
- Controversial
- Uncontroversial
- New
- Best
- Controversial
- Uncontroversial

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

scientific article published on November 2006

Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054

scientific article published on 17 June 2019

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

scientific article